🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #LOVE 927.8x
2. #CRMD 350.6x
3. #NGL 162.0x
4. #JBS 91.1x
5. #CMBM 40.0x

#OptionFlow #OptionsTrading #Trading

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE)

#CRMD CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRMD/cor-medix-inc-...

CorMedix Therapeutics Announces Leadership and Board Updates CorMedix Therapeutics (Nasdaq: CRMD) announced executive and board changes on January 8, 2026. CEO Joseph Todisco signed an extended employment contract and will also become Chairman of the Board, succeeding Myron Kaplan, who will move to a newly created role of Lead Independent Director. CorMedix said it has evolved into a multi-product, diversified commercial company with positive cashflow and a strong pipeline. The company also appointed Mike Seckler as EVP & Chief Commercial Officer; Seckler brings prior roles as CEO of Evome Medical Technologies, COO of FerGene, and head of global marketing at Ferring.

#CRMD CorMedix Therapeutics Announces Leadership and Board Updates

www.stocktitan.net/news/CRMD/cor-medix-ther...

True executive function is not the ability to push through, but the wisdom to recognise when the 'Tax' is too high and the only move is to surrender to the floor.
"The Energy Debt: Why living with ADHD and/or Fibromyalgia can be a fueling paradox" #CRMD #TheFuelingParadox (2/2)

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath CorMedix (Nasdaq: CRMD) reported interim results from its ongoing real‑world evidence study of DefenCath in adult hemodialysis patients with central venous catheters, conducted with U.S. Renal Care. Based on data through Sept 30, 2025 for ~7,000 patients in Year 1, DefenCath use showed a 72% reduction in catheter‑related bloodstream infections (CRBSI) and a 70% reduction in hospitalizations secondary to CRBSI versus historical controls. More than 3,000 patients per month are receiving DefenCath at USRC facilities. The company highlighted potential healthcare cost reductions given CMS estimates of >$3B annual CRBSI costs in ESRD and average CRBSI hospitalization costs of ~$63,000.

#CRMD CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

www.stocktitan.net/news/CRMD/cor-medix-ther...

Managing patients with cardiorenal metabolic disease Introduction Cardiorenal metabolic disease (CRMD) refers to the interconnected dysfunctions of the cardiovascular, renal, and metabolic systems including chronic kidney disease (CKD), diabetes…

This learning article examines the pathophysiology of cardiorenal metabolic disease, medication optimisation strategies and the role of the pharmacist in medication management and patient education

#ukpharmacy #CRMD #cardiovascularhealth

pharmaceutical-journal.com/article/ld/m...

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance CorMedix (Nasdaq: CRMD) reported Q3 2025 net revenue $104.3M and pro forma net revenue $130.8M, driven by higher-than-expected outpatient DefenCath utilization and partial-quarter Melinta sales. The company posted Q3 net income $108.6M and adjusted EBITDA $71.9M, with basic and diluted EPS of $1.42 and $1.26. Management raised FY 2025 pro forma net revenue guidance to $390–$410M and fourth-quarter revenue guidance to $115–$135M, and increased fully synergized pro forma adjusted EBITDA guidance to $220–$240M. The Melinta acquisition closed August 29, 2025; estimated 2025 synergy capture is ~$30M of an expected $35–$45M annual run rate. Cash and short-term investments were $55.7M at Sept. 30, 2025, with projected year-end cash ~$100M. ReSPECT Phase III enrollment completed; top-line data expected in 2Q 2026.

#CRMD CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

www.stocktitan.net/news/CRMD/cor-medix-inc-...

CRMD Ice Cream Closes Lewis Center Location - Ashley Kimmel

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath CorMedix (Nasdaq: CRMD) announced that DefenCath, its FDA‑approved antimicrobial catheter lock solution, received an Innovative Technology designation from Vizient on Oct. 23, 2025.DefenCath is approved for a limited population of adult patients on chronic hemodialysis via central venous catheter and in a Phase 3 LOCK IT-100 study showed a 71% reduction in risk of catheter-related bloodstream infections with adverse events comparable to control. CorMedix is conducting a real‑world evidence study in >2,000 patients and expects interim data around year-end. Vizient represents approximately $156 billion in annual purchasing volume.

#CRMD CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

www.stocktitan.net/news/CRMD/cor-medix-inc-...

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance CorMedix (Nasdaq: CRMD) reported preliminary unaudited Q3 2025 results and raised 2025 pro forma net revenue guidance. Key figures include Q3 pro forma net revenue >$125M, DefenCath Q3 net revenue >$85M, and Q3 unaudited company net revenue >$100M. Management raised full‑year 2025 pro forma net revenue guidance to at least $375M and expects Q3 adjusted EBITDA ≥ $70M.The company forecasts at least $30M of go‑forward operating synergies before year‑end 2025 from the Melinta integration, with an additional $5–$15M targeted in 2026. Cash and short‑term investments were approximately $56M on Sept 30, 2025, with a projected year‑end cash balance of ~$100M. Clinical update: Phase III ReSPECT enrollment complete; data expected 2Q 2026.

#CRMD CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

www.stocktitan.net/news/CRMD/cor-medix-inc-...

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Hedge Fund Elliott Management's Q2 Moves Include Positions Tied To S&P 500, Nasdaq, Nvidia (CORRECTED) Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions ...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter Elliott Management places new bets against the market in the second quarter, while taking a new long position...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter Elliott Management places new bets against the market in the second quarter, while taking a new long position...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter - ARM Holdings (NASDAQ:ARM), Booking Holdings (NASDAQ:BKNG) Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter Elliott Management places new bets against the market in the second quarter, while taking a new long position...

#ARM #BKNG #BMRN #Chip #Stocks #CRMD #CSCO #DLR #Elliott #Management #ETWO

Origin | Interest | Match

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings CorMedix (NASDAQ:CRMD) has announced a transformational acquisition of Melinta Therapeutics for $300 million in upfront consideration, including $260M in cash and $40M in CRMD equity. The deal adds seven marketed products to CorMedix's portfolio and is expected to generate pro forma 2025 combined revenues of $305-335 million.The acquisition brings significant strategic value with expected annual run-rate synergies of $35-45 million and is projected to be accretive to EPS with double-digit accretion in 2026. The deal includes potential additional payments of up to $25 million in regulatory milestones and royalties on REZZAYO™ and MINOCIN® sales.The transaction is expected to close by September 1, 2025, subject to HSR Act requirements. Melinta's portfolio, which generated $120 million in 2024 revenue, includes key products like REZZAYO™, which has potential peak sales exceeding $200 million in its expanded indication.

#CRMD CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

www.stocktitan.net/news/CRMD/cor-medix-to-a...

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update CorMedix (NASDAQ:CRMD) reported strong Q2 2025 financial results, highlighted by $39.7 million in net revenue from DefenCath sales, compared to $0.8 million in the same period last year. The company achieved net income of $19.8 million ($0.29 per share), a significant turnaround from a net loss of $14.2 million in Q2 2024.For the first half of 2025, CorMedix recorded $78.8 million in net revenue and net income of $40.5 million ($0.60 per share). The company maintains a strong financial position with $190.7 million in cash and short-term investments. Operating expenses increased 18% year-over-year to $18.3 million in Q2 2025.In a significant strategic move, CorMedix announced the acquisition of Melinta Therapeutics LLC, with an expected closing date of September 1, 2025.

#CRMD Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRMD/cormedix-inc-r...

CorMedix Raises $85M in Stock Offering to Fuel R&D and Strategic Acquisitions Biotech firm secures $85M through 6.6M share offering, backed by RBC Capital Markets. Proceeds target R&D expansion and strategic acquisitions. Closing June 30. Learn more.

#CRMD CorMedix Inc. Announces Pricing of Public Offering of Common Stock

www.stocktitan.net/news/CRMD/cor-medix-inc-...

CorMedix Announces Massive $85M Stock Offering: Strategic Acquisitions and R&D Expansion Planned CorMedix plans strategic acquisitions and R&D expansion with $85M stock offering led by RBC Capital Markets. See full investment terms and growth strategy.

#CRMD CorMedix Inc. Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/CRMD/cor-medix-inc-...

#CRMD shares soar 18% as DefenCath expands its reach with a major dialysis provider, now set to treat 50% more patients than expected. The company also raised its Q2 sales outlook to $35–$40M, signaling accelerating demand and commercial momentum.
#CorMedix
prismmarketview.com/cormedix-sha...

PRISM Mid-Day Movers:
#COMPASSPathways ( #CMPS) dives 45%
#wearehims & Hers ( #HIMS) drops 30%
Other PRISM Mid-Day Movers:
• CorMedix Inc. ( #CRMD) up 17.85%
• #skyebioscience , Inc. ( #SKYE) up 28.66%
• Houston American Energy Corp. ( #HUSA) up 43.78%
prismmarketview.com/prism-mid-da...

CorMedix inc. Announces Customer Implementation CorMedix (NASDAQ: CRMD) announces a significant expansion in its Large Dialysis Organization (LDO) customer implementation of DefenCath. The customer will begin implementing DefenCath in the second half of 2025, targeting 50% more patients than initially planned. Due to this expansion and other positive developments, CorMedix has increased its Q2 net sales guidance from $31 million to $35-40 million range. The company expects modest revenue contribution starting June 2025, with growth anticipated in the latter half of the year. The implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections.

#CRMD CorMedix inc. Announces Customer Implementation

www.stocktitan.net/news/CRMD/cor-medix-inc-...

CorMedix Hits Major Milestone: Reports First Ever Profitable Quarter with $39.1M Revenue, Raises Guidance CorMedix achieves profitability with $20.6M net income as DefenCath sales surge. Plus: New Phase 3 trial launch and raised revenue guidance. See full results.

#CRMD CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CRMD/cor-medix-inc-...

CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration Strong Q1 drives CorMedix to boost H1 2025 sales forecast to $62-70M. $22.5M EBITDA showcases profitable growth as DefenCath expansion continues. Full analysis inside.

#CRMD Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

www.stocktitan.net/news/CRMD/cormedix-inc-a...